Ibrahim Al-khyate։ New Evidence on Triple Antithrombotic Therapy After Anterior Myocardial Infarction
Ibrahim Al-khyate, Cardiology Resident at Ministry of Health and Population – Egypt, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Clinical and Applied Thrombosis/Hemostasis, adding:
”Excited to share our latest publication in Clinical and Applied Thrombosis/Hemostasis!
Our updated systematic review and meta-analysis has now been published in SAGE Journals.
7 studies | 2,273 patients
Research question
Does adding prophylactic triple antithrombotic therapy to dual antiplatelet therapy after anterior myocardial infarction reduce the risk of left ventricular thrombus without compromising patient safety?
Main findings
- No significant reduction in left ventricular thrombus
- No reduction in all-cause mortality
- No reduction in thromboembolic events
Increased risk of major bleeding
Take-home message:
Current evidence does not support the routine use of prophylactic triple antithrombotic therapy after anterior myocardial infarction.
Antithrombotic therapy should be individualized, balancing thrombotic and bleeding risks.
Sincerely grateful to my co-authors and mentors for their dedication, insightful discussions, and collaboration throughout this project.
Looking forward to future collaborations and continuing to contribute to meaningful cardiovascular research.”
Title: Triple Antithrombotic Therapy vs Dual Antiplatelet for Prevention of Left Ventricular Thrombus After Anterior Myocardial Infarction: An Updated Meta-Analysis
Authors: Mustafa Abomohsen, Ibrahim Elkhayat, Ahmed Elmorsy Mohamed, Abdul Hakim Almakadma, Zeyad Kholeif, Ahmed Farid Gadelmawla, Ameer Awashra, Muhammed A. Youssef, Osamah AlQassab, Mohamed Ghannam, Vikas Patel, Azad Mojahedi, Iyad Idries, Meena Farid, Moshe Gunsburg, Hal L. Chadow
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 17:08Khusi Dhara: Why Women Need to Pay Attention to Iron
-
Sep 3, 2026, 16:54Ralf Ludwig։ Testing Human-Targeted Therapies in a Human Immune System
-
Sep 3, 2026, 16:35Mohsen Salimi: Non-Contrast Chest CT as a Biomarker for Mild-to-Moderate Anemia
-
Sep 3, 2026, 16:10Tanzeel Alamin Almahdi Gorashi: NLR as an Accessible Biomarker for Monitoring Pediatric Sickle Cell Anemia
-
Sep 3, 2026, 15:42Manuel De Jesus: Innovating Anemia Monitoring Through Biomedical Engineering and Digital Technology
-
Sep 3, 2026, 15:37Hadis Nabipoor: QICL2026 Highlights the Critical Importance of Transfusion Safety
-
Sep 3, 2026, 15:32Gopal Patidar: The ISBT Haemovigilance Working Party Sharing Knowledge and Promoting Best Practices
-
Sep 3, 2026, 15:24Bhalchandra Kawdikar: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 15:18Massimo Martino: Redefining Allogeneic Transplantation in Myelofibrosis